- Pyrrolidine ester dipeptidyl peptidase inhibitors and its pharmaceutical composition
-
The invention relates to pyrrolidine ester (boronate ester) DDP - IV inhibitors, dipeptidyl peptidase - IV participation in diseases such as diabetes in particular 2 type diabetes, tumor or other treatment and prevention of disease in a useful role. This invention relates to pharmaceutical compositions comprising these compounds and in the prevention or treatment of dipeptidyl peptidase - IV in these diseases.
- -
-
Paragraph 0335-0337
(2018/02/04)
-
- SOLID CITRATE AND TARTRATE SALTS OF DPP-IV INHIBITORS
-
This invention relates to DPP-IV inhibitory citrate or tartrate salts of pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that are physically and chemically stable, substantially non-deliquescent solids under ambient conditions.
- -
-
Page/Page column 30-33
(2008/06/13)
-
- HETEROCYCLIC BORONIC ACID COMPOUNDS
-
Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C (CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form a fused cyclopropyl; and optionally, one of the bonds in the ring containing X is a double bond; and CriRii, R1, R1, R3, R4 and R5 are as described herein. Methods for preparing these compounds, and methods for treating diabetes, especially Type II diabetes, and other related diseases are described using the compounds of formula I in pharmaceutical compositions which contain these compounds. Pharmaceutical compositions which contain combinations of these compounds with other antidiabetic agents are also described herein.
- -
-
Page/Page column 120; 132
(2008/06/13)
-
